

1 **Pre-existing cancer cells and induced fibroblasts are key cells for early** 2 **chemoresistance in ovarian cancer**

3
4 Langyu Gu^{1,#}, Shasha He^{2,#}, Linxiang Wu^{3,#}, Yu Zeng⁴, Yang Zhang³, Chenqing
5 Zheng¹, Chuling Wu³, Huishan Xu³, Xiaoyan Zhang³, Hongwei Shen³, Shuzhong
6 Yao³, Yufeng Ren^{2,*}, Guofen Yang^{3,*}

7
8 ¹ State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-sen University,
9 Guangzhou, 510275, Guangdong, China

10 ² Department of Radiation Oncology, the First Affiliated Hospital, Sun Yat-sen University,
11 Guangzhou, 510060, Guangdong, China

12 ³ Department of Gynecology, the First Affiliated Hospital, Sun Yat-sen University,
13 Guangzhou, 510060, Guangdong, China

14 ⁴ Department of Nuclear Medicine, the First Affiliated Hospital, Sun Yat-sen University,
15 Guangzhou, 510060, Guangdong, China

16
17 # authors contributed equally

18
19 Correspondence:

20 *Yufeng Ren: renyuf@mail.sysu.edu.cn

21 *Guofen Yang: yangguof@mail.sysu.edu.cn

22 23 **Running title:**

24 Chemoresistance at the single cell level in ovarian cancer

25 **Statement of significance**

26 We have identified key cells and core gene networks for early
27 chemoresistance in ovarian cancer.

28 29 **Conflict of Interest**

30 The authors declare no potential conflicts of interest.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 Chemoresistance has long been a significant but unresolved issue in the treatment
33 of various cancers, including the most deadly gynecological cancer, the high-
34 grade serous ovary cancer (HGSOC). In this study, single nuclei transcriptome
35 analyses were utilized to identify key cells and core networks for chemoresistance
36 in HGSOC patients with different early responses to platinum-based
37 chemotherapy at the single-cell level. Biomarkers for chemoresistance were also
38 screened using bulk transcriptome data from independent cohorts with larger
39 sample sizes. A total of 62,482 single cells from six samples were analyzed,
40 revealing that chemoresistant cancer cells (Epithelial cells_0) pre-existed within
41 individual patient before treatment. Two network modules formed with hub genes
42 such as hormone-related genes (ESR1 and AR), insulin-related genes (INSR and
43 IGF1R), and CTNNB1, were significantly overexpressed in these cells in the
44 chemoresistant patient. BMP1 and TPM2 could be promise biomarkers in
45 identifying chemoresistant patients before chemotherapy using bulk
46 transcriptome data. Additionally, chemotherapy-induced fibroblasts
47 (Fibroblasts_01_after) emerged as key stromal cells for chemoresistance. One
48 network module containing one subnetwork formed by cholesterol biosynthesis-
49 related genes and one subnetwork formed by cancer-related genes such as STAT3
50 and MYC, was significantly overexpressed in these cells in the chemoresistant
51 patient. Notably, the NAMPT-INSR was the most prioritized ligand-receptor pair
52 for cells interacting with Fibroblasts_01_after cells and Epithelial cells_0 cells to
53 drive the up-regulation of their core genes, including IL1R1, MYC and INSR
54 itself. Our findings deepen the understandings about mechanisms of early
55 chemoresistance in HGSOC patients.

56

57 **Key words:**

58 chemoresistance, pre-existing cancer cells, induced fibroblasts, NAMPT-INSR,
59 ovarian cancer, single cell

60 **Introduction**

61 Chemoresistance presents a formidable obstacle in the effective treatment
62 of various cancers, including the high-grade serous ovarian cancer (HGSOC),
63 which is the most lethal gynecologic malignancy (1). While initial responses to
64 chemotherapy are favorable for most patients (2), approximately one-third of
65 patients responding poorly to chemotherapy, with limited further treatment
66 options available (3). Furthermore, even patients initially responsive well to
67 chemotherapy may eventually develop chemoresistance, contributing to high
68 mortality rates in HGSOC (2). Despite decades of clinical application of
69 chemotherapy, the mechanism behind chemoresistance remains largely unknown.
70 Although individual chemoresistant targets have been identified using classical
71 biological experimental methods, their efficacy is usually limited due to the
72 inherent complexity of biological organisms. We thus need to analyze the
73 mechanism of chemoresistance at a higher resolution and at the systemic network
74 level.

75
76 Cell populations are fundamental to the execution of biological functions
77 in humans, and chemoresistance represents a selection process favoring cell
78 populations with adaptive fitness phenotypes. A critical question arises: Do
79 different responses to chemotherapy pre-exist in patients before treatment, or are
80 they acquired during treatment? Answering these questions necessitates a single-
81 cell level analysis, including the differentiation of cancer cells with varying
82 chemotherapy responses and the interactions among cells in the tumor
83 microenvironments of patients with different responses. Previous studies in
84 different cancer types, such as breast cancer, rectal cancer, and oral squamous
85 cell carcinomas, have revealed diverse mechanisms of chemoresistance, with
86 either showing pre-existing genetic mutations for chemoresistance (4), or
87 demonstrating acquired transcriptional profile reprogramming during treatment
88 (5), or both (6) . These findings underscore the need for specific analyses tailored

89 to each cancer type. One recent study has provided valuable insights into the
90 mechanisms of chemoresistance in HGSOc, but it focused on metastatic sites (7),
91 leaving the mechanisms at the primary sites of HGSOc relatively unclear.
92 Furthermore, the use of platinum-free intervals to characterize chemoresistance
93 remains controversial and may not directly reflect chemoresistance (8).

94

95 Therefore, in this study, we sought to investigate and compare cellular
96 composition and corresponding transcriptional profiles at the primary sites before
97 and after platinum-based chemotherapy in patients with varying responses at the
98 single-cell level. Our objectives were to address the following questions: Which
99 cell types are key cells for early chemoresistance? Are the corresponding gene
100 co-expression networks pre-existing or acquired? What are specific cellular
101 interactions in the microenvironments in chemoresistant patients? Our findings
102 will deepen our understandings about mechanisms of chemoresistance, and can
103 be helpful for finding potential biomarkers and therapeutic targets for early
104 chemoresistant HGSOc patients.

105

106 **Materials and Methods**

107 **Sampling and Library Construction**

108 This study was approved by the Ethics Committee for Clinical Research
109 and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University
110 (ethics approval No. 2021726). Six fresh paired primary HGSOc samples before
111 and after chemotherapy were collected from three patients who received
112 neoadjuvant chemotherapy (NACT) between 2021 and 2022 at the First
113 Affiliated Hospital, Sun Yat-sen University in Guangzhou, China. Clinical
114 information can be found in the Supplementary File 1. The chemotherapy
115 regimen consisted of three cycles of paclitaxel plus carboplatin. Paired samples
116 were obtained during laparoscopy and interval debulking surgery before and after
117 chemotherapy. Fresh tissues were immediately frozen in liquid nitrogen and

118 transported by dry ice. Single nuclei transcriptome libraries construction and
119 sequencing were conducted by Novogene (China) following 10x Genomics
120 instructions (<https://support.10xgenomics.com>). Briefly, libraries were
121 constructed using the Chromium Next GEM Chip G Single Cell Kit, 48 rxns (PN-
122 100020), and Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead
123 Kit v3.1, 16 rxns PN-1000121. Libraries with PE150 (paired-end reads, 150bp)
124 were sequenced on an Illumina NovaSeq 6000.

125

126 Chemotherapy Response Evaluation

127 All patients underwent baseline 18F-FDG PET/CT before and after
128 chemotherapy (Figure 1A). 18F-FDG PET/CT was performed after at least 6
129 hours of fasting and with a glucose level lower than 10 mmol/L. The PET/CT
130 scan coverage ranged from the top of the head to the mid-thigh. The ordered-
131 subset expectation maximization iterative reconstruction method was used to
132 reconstruct the data. The total metabolic tumor volume (tMTV) and total lesion
133 glycolysis (TLG) were measured and calculated. Based on PERCIST 1.0 (9), we
134 differentiated patients as partial responses to chemotherapy (PR1 and PR2) and
135 progress disease (PD) (we named these IDs for this study and they were not used
136 to identify patients outside the research group) (Figure 1B).

137

138 Data Pre-processing

139 Raw data were analyzed with 10x Genomics Cell Ranger 6.1.1. The
140 GRCh38 Ensembl build genome (refdata-gex-GRCh38-2020-A) was used as the
141 reference. The filtered feature barcode matrix was used for further data analysis.
142 The Seurat v4 R package was used for data pre-processing (10). Only genes
143 expressed in at least three cells, and cells with at least 200 unique Molecular
144 Identifiers (UMI) were retained. Quality control metrics were plotted for
145 individual samples and used for filtering cells with aberrantly high UMI, which
146 could be originated from cell doublets or multiplets. The PercentageFeatureSet()

147 function was used to calculate the percentage of counts originating from
148 mitochondrial DNA (mtDNA). Low-quality or dead cells with abnormal
149 mitochondrial contamination were removed. Cell clusters with fewer than 10
150 cells were also removed. Cell cycle effects were evaluated with
151 CellCycleScoring() function. Doublets were assessed using the DoubletFinder
152 v2.0 R package (11).

153

154 Based on the plotting results (Supplementary File 2), quality control was
155 performed for each sample. For PR1_before (pre-chemotherapy sample of patient
156 1 with partial response to chemotherapy), cells with $200 < \text{UMI} < 7500$, mtDNA
157 percentage < 8 , ribosome percentage < 4 were retained, and 984 doublets were
158 removed. Similarly, for PR1_after (post-chemotherapy sample of patient 1 with
159 partial response to chemotherapy), cells with $200 < \text{UMI} < 5000$, mtDNA
160 percentage < 2 , ribosome percentage < 1 were retained, and 831 doublets were
161 removed. For PR2_before (pre-chemotherapy sample of patient 2 with partial
162 response to chemotherapy), cells with $200 < \text{UMI} < 7500$, mtDNA counts $< 6\%$,
163 ribosome percentage < 2 were retained, and 1057 doublets were removed. For
164 PR2_after (post-chemotherapy sample of patient 2 with partial response to
165 chemotherapy), cells with $200 < \text{UMI} < 4300$, mtDNA percentage $< 2.5\%$,
166 ribosome percentage < 2 were retained, and 1119 doublets were removed. For
167 PD_before (pre-chemotherapy sample of the chemoresistant patient), cells with
168 $200 < \text{UMI} < 6000$, mtDNA percentage < 10 , ribosome percentage < 2 were
169 retained, and 144 doublets were removed. For PD_after (post-chemotherapy
170 sample of the chemoresistant patient), cells with $200 < \text{UMI} < 6000$, mtDNA
171 percentage < 1 , ribosome percentage < 2 were retained, and 367 doublets were
172 removed.

173

174 Data Integration, Clustering, and Differential Gene Expression Analysis

175 The preprocessed data were used for data integration analysis using Seurat
176 to correct batch effects among samples (10). 2000 highly variable expressed
177 genes detected for each sample were used to find anchors for data integration.
178 Subsequently, the integrated data was scaled, and the principal components were
179 computed. The top 30 principal components were identified using an elbow plot.
180 Clustering identification was performed at a proper resolution that can
181 differentiate major cell types. The UMAP dimensionality reduction was used for
182 visualization. Differential expressed (DE) genes were identified with a significance
183 threshold of adjusted p value < 0.05 and $\log_2\text{FoldChange} > 0.5$. KEGG pathways
184 enrichment analyses were performed using the STRING database ([https://string-](https://string-db.org/)
185 [db.org/](https://string-db.org/)) (12).

186

187 Malignant Cells Inference

188 Malignant cells were inferred based on genomic copy number variation
189 (CNV) using CopyKAT v1.1.0 (13). Cells with extensive genome-wide copy
190 number aberrations (aneuploidy) were considered as malignant tumor cells.
191 Parameters were set as `ngene.chr=10`, `win.size=25`, `KS.cut=0.1`,
192 `distance="euclidean"`. Only cells that met the criteria were presented. For the
193 PR2_after which contained only a small number of epithelial cells (15 cells), we
194 assumed that all these epithelial cells were malignant cells, since they all
195 overexpressed malignance cell markers.

196

197 Gene Co-expression Network Construction

198 hdWGCNA (14) was used to construct high dimensional gene co-
199 expression network modules for target cell clusters. Genes expressed in at least
200 5% of cells were used for analyses. Batch effects were corrected during analyses
201 by setting `group.by` and `group.by.vars` parameters. The number of cells to be
202 aggregated for metacells construction was 25, and the `max_shared` was set as 10
203 as default. The TestSoftPowers was used to determine a proper value of the soft

204 power threshold. The implemented AddModuleScore function was applied to
205 compute hub genes signature scores for each module. Differential module
206 eigengene analysis was performed between target cell groups. Hub genes
207 overexpressed in the target cells in the network modules were further used to
208 construct protein-protein network using the STRING database (12). The
209 thickness of network edges represents the strength of data support. The minimum
210 required interaction score was set as 0.7 (high confidence). Only genes with
211 interaction degrees >1 were presented.

212

213 Survival Analyses

214 Survival analyses were conducted using three publicly available bulk
215 transcriptome datasets with clinical information, including GSE102073 (n=70),
216 PRJNA866991 (n=41), and GSE32062 (n=260). Kaplan-Meier (K-M) survival
217 curves were constructed using the survival 3.5 R package (15).

218

219 Bulk Transcriptome Analyses

220 For the GSE102073 cohort, the normalized gene expression matrix was
221 obtained directly from the GEO database. For the PRJNA866991 cohort, raw
222 reads were retrieved from the NCBI database and aligned to the GRCh38
223 Ensembl build human genome using HISAT2 v2.1.0 (16). SAMTOOLS v1.7
224 (17,18) was utilized to convert sam files to bam files, sort and index bam files,
225 and obtain the final counts. Featurecounts v2.0.4 (19) was used to obtain the
226 counts at the gene level. The DESeq2 v1.38.3 (20) was employed to normalize
227 the count files and generate the final expression matrix. For the GSE32062 cohort,
228 CEL files were first downloaded from the GEO database. The affy v1.74 R
229 package (21) was used to process the CEL files, and rma was applied for
230 normalization. The hgu133plus.db was used to extract the gene expression matrix
231 at the gene level.

232

233 Cell-Cell Interaction Analyses

234 Nichenetr (22) was used to identify prioritized ligand-receptor-target genes
235 involved in the interactions from senders to receivers under different conditions.
236 All genes expressed in at least 10% of receiving cells were used as the
237 background geneset.

238

239 RNA Velocity Analyses

240 RNA velocity (the change in mRNA abundance calculated by relating the
241 abundance of unspliced and spliced mRNA) was estimated using Scvelo (23)
242 following the instructions (<https://scvelo.readthedocs.io/en/stable/>). The
243 stochastic model was chosen to account for stochasticity in gene expression, and
244 the combination of velocities across genes was used to estimate the future state
245 of individual cells.

246

247 Data Availability

248 All data produced in the present study are available upon reasonable
249 request to the authors.

250

251 Results

252 Cell atlas before and after chemotherapy in patients with different responses


253 We collected six samples at primary ovary sites from three HGSOC
254 patients paired before and after chemotherapy. The responses to chemotherapy
255 were evaluated using PET/CT (Figure 1A and Figure 1B). The results of tMTV
256 and TLG of each patient before and after chemotherapy were given in Figure 1B.
257 Based on PERCIST 1.0 (9), we differentiated patients as partial responses to
258 chemotherapy (PR1 and PR2) and progress disease (PD). After quality control, a
259 total of 62482 single cells were grouped into nine major clusters, including 12668
260 epithelial cells (KRT19⁺), 41522 fibroblasts (DCN⁺), 1825 T cells (CD96⁺), 4850
261 Macrophages (CD163⁺), 1120 Endothelial cells (VWF⁺), 75 Lymphatic

262 endothelial cells (FLT4⁺), 213 B cells (MZB1⁺), 43 Schwann cells (LGI4⁺), and
263 166 Ciliated-secretory intermediate cells (CFAP54⁺FOXJ1⁺PAX8⁺) (24,25)
264 (Figure 1C). Malignant cells inference revealed that malignant cells were mainly
265 epithelial cells (Figure 1D), which is consistent with the pathological
266 characteristics of HGSOC as an epithelial cancer. A small portion of ciliated-
267 secretory intermediate cells were also identified as malignant cells, which can be
268 explained since they were assumed to be the main origin of HGSOC (24,25).
269 Expression profiles of corresponding markers in each cell type were provided in
270 Figure 1E. The cell numbers and ratios in each major cell cluster from individual
271 patients were also presented in Figure 1F. The distribution of major cell clusters
272 in each sample among patients before and after chemotherapy were illustrated in
273 Figure 1G.


274

275



276



B



277



278

279 **Figure 1** Schematic of sampling and analysis results. (A) Schematic of sampling. Fresh paired primary samples
280 before and after chemotherapy were collected from three patients who received neoadjuvant chemotherapy
281 (NACT). The chemotherapy regimen consisted of three cycles of paclitaxel plus carboplatin. PET/CT was used
282 to evaluate chemotherapy responses before and after chemotherapy for each patient. Paired samples were collected
283 during laparoscopy and interval debulking surgery before and after chemotherapy. Single nuclei transcriptome
284 libraries constructions were conducted following 10 x Genomics instructions. (B) Chemotherapy responses
285 evaluation. tMTV (total metabolic tumor volume) and TLG (total lesion glycolysis) were used to evaluate
286 chemotherapy responses. PR1 represents patient 1 with a partial response to chemotherapy, PR2 represents patient
287 2 with a partial response to chemotherapy, and PD represents progressive disease (chemoresistant patient). (C)
288 The UMAP plot of cell atlas of integrated samples showing major cell clusters. (D) Malignant cells inference.
289 Aneuploid cells (malignant cells) and diploid cells (non-malignant cells) were identified. (E) The dot plot of
290 marker genes expression for each major cell cluster. (F) Cell numbers and cell ratios of each major cell cluster in
291 each individual sample. (G) The UMAP plot of cell atlas showing major cell clusters in each individual sample
292 among patients before and after chemotherapy. PD_after represents the post-chemotherapy sample of the
293 chemoresistant patient, PD_before represents the pre-chemotherapy sample of the chemoresistant patient,
294 PR1_after represents the post-chemotherapy sample of patient 1 with partial response to chemotherapy,
295 PR1_before represents the pre-chemotherapy sample of patient 1 with partial response to chemotherapy,
296 PR2_after represents the post-chemotherapy sample of patient 2 with partial response to chemotherapy, and
297 PR2_before represents the pre-chemotherapy sample of patient 2 with partial response to chemotherapy.

298


299 **Chemoresistant cancer cells were pre-existing in the PD patient**

300

301 Five subclusters of epithelial cells were identified in total (Figure 2A and
302 2B). No genes were specifically overexpressed in Epithelial cells_0, indicating
303 that this subcluster represented a common cancer cell type. Epithelial cells_1
304 specifically overexpressed MKI67 and enriched cell proliferation-related
305 pathways, such as homologous recombination, DNA replication, and the cell
306 cycle. Epithelial cells_2 specifically overexpressed the hypoxia-related gene
307 PFKFB. Epithelial cells_3 specifically overexpressed DOCK8 and PTPRC, and
308 enriched immune response-related pathways, such as the B cell receptor and T
309 cell receptor pathways. Epithelial cells_4, which only appeared in the partial
310 response after chemotherapy, specifically overexpressed DACH2 and OVGPI1,
311 and enriched cancer-related pathways (Figure 2C, 2D).

312

313 Cell proportion analysis showed that Epithelial cells_0 cells were highly
314 enriched in the PD_after, indicating its chemoresistant character (Figure 2E and
315 2F). DE genes retrieved from comparisons among samples after chemotherapy
316 for each subcluster also revealed that Epithelial cells_0 cells enriched many
317 cancer-related pathways in the PD_after, such as the Wnt signaling pathway, the
318 MAPK signaling pathway, the insulin signaling pathway, the cellular senescence
319 pathway, and the longevity regulating pathway (Figure 2G). In contrast, although
320 other subclusters also remained after chemotherapy in the PD_after, their
321 proportions were largely reduced, and no cancer-related pathways were enriched,
322 indicating their fragility to chemotherapy. Thus, we proposed that Epithelial
323 cells_0 cells were the key cancer cells for early chemotherapy responses. It is
324 worth noting that clustering analysis using cell average transcriptional profiles
325 clustered Epithelial cells_0 cells based on individual patient ID rather than
326 treatment condition (before or after chemotherapy) (Figure 2H), indicating that
327 transcriptional profiles for chemotherapy responses were largely pre-existing in
328 Epithelial cells_0 cells in individual patients before chemotherapy.



329


330 **Figure 2** (A) The UMAP plot of cell atlas for five epithelial cells subclusters. (B) The UMAP plot of cell atlas
 331 showing five epithelial cells subclusters in each individual sample among patients before and after chemotherapy.
 332 PD_after represents the post-chemotherapy sample of the chemoresistant patient, PD_before represents the pre-
 333 chemotherapy sample of the chemoresistant patient, PR1_after represents the post-chemotherapy sample of
 334 patient 1 with a partial response to chemotherapy, PR1_before represents the pre-chemotherapy sample of patient
 335 1 with a partial response to chemotherapy, PR2_after represents the post-chemotherapy sample of patient 2 with
 336 a partial response to chemotherapy, PR2_before represents the pre-chemotherapy sample of patient 2 with a partial
 337 response to chemotherapy. (C) The dot plot of marker genes expression for epithelial cells subclusters. (D) KEGG
 338 pathway enrichment for epithelial cells subclusters. (E) Cell numbers and cell ratios of cell subclusters in each
 339 individual sample. (F) Cell ratio comparisons of the Epithelial cells_0 subcluster between samples before and
 340 after chemotherapy in each patient. (G) KEGG pathway enrichment for the Epithelial cells_0 subcluster among
 341 samples after chemotherapy. (H) Sample clustering using cell average transcriptional profiles clustered Epithelial
 342 cells_0 cells based on individual patient ID rather than treatment condition (before or after chemotherapy).
 343

344 Gene co-expression networks construction further supported the above
 345 results. We identified six co-expression modules for Epithelial cells_0 cells in
 346 total. Module eigengene (ME) represents the first principal component of the
 347 gene expression matrix comprising each module, and was thus used to summarize

348 the gene expression profile of the entire module. Figure 3A presented the
349 summarization of the expression of each module obtained by calculating gene
350 signature scores from MEs for the top 25 hub genes for each module. To correct
351 batch effects, harmony batch correction was applied to produce harmonized MEs
352 (hMEs) (Figure 3B). We can see that, again, pre- and post- chemotherapy
353 samples from the same patient expressed similar modules (Figure 3B). For
354 example, the PD patient overexpressed M3 and M4 modules both before and after
355 chemotherapy. Differential module eigengene analysis revealed that no module
356 was significantly overexpressed in the post-chemotherapy sample when
357 compared to the pre-chemotherapy sample from the same patient. For example,
358 although the adjust p value of M3 in the PD_after was significant when compared
359 to PD_before, its foldchange was small (Figure 3C left). Although the adjust p
360 values of M3 and M4 modules were significant in the PR1_after when compared
361 to the ones in the PR1_before, they actually expressed little in these samples
362 (Figure 3C middle). This can be also applied to M4 and M6 modules in the PR2
363 patient (Figure 3C right). These results confirmed again that the transcriptional
364 profiles for different chemotherapy responses were pre-existing in cancer cells
365 before chemotherapy.

366

367 Notably, when comparing Epithelial cells_0 cells among samples after
368 chemotherapy, M3 and M4 modules were significantly overexpressed in
369 Epithelial cells_0 cells in the PD_after when compared to the ones in either
370 PR1_after or PR2_after (Figure 3D), indicating the chemoresistant characters of
371 these two modules. Further protein-protein co-expression networks using these
372 module genes overexpressed in the PD_after showed that insulin-related
373 receptors (INSR and IGF1R), hormone receptor (AR), NCOR2, and SMAD2
374 formed a tight connective network in module M3, and a tight network with
375 CTNNB1 and ESR1 as the core hubs in module M4 (Figure 3E).




376

377 **Figure 3** Gene co-expression networks construction and comparisons for Epithelial cells_0. (A) The UMAP plots
 378 of the hub gene signature score for each module constructed for Epithelial cells_0. (B) Violin plots of the
 379 harmonized module eigengenes (hMEs) in each sample for each module. (C) Differential module eigengene
 380 comparisons between post- and pre-samples within each individual patient. (D) Differential module eigengene
 381 comparisons between the PD_after and the PR1_after or the PR2_after, respectively. (E) Co-expression networks
 382 visualization of Module 3 and Module 4. PD_after: post-chemotherapy sample of the chemoresistant patient.
 383 PD_before: pre-chemotherapy sample of the chemoresistant patient. PR1_after: post-chemotherapy sample of the
 384 patient 1 with partial response to chemotherapy. PR1_before: pre-chemotherapy of the patient 1 with partial
 385 response to chemotherapy. PR2_after: post-chemotherapy sample of the patient 2 with partial response to
 386 chemotherapy. PR2_before: pre-chemotherapy of the patient 2 with partial response to chemotherapy.

387

388 The presence of pre-existing chemoresistance transcriptional profiles in
 389 cancer cells before chemotherapy lays the foundation for the search for relevant
 390 pre-treatment biomarkers. Survival analyses were thus conducted using publicly
 391 available bulk transcriptome data with progression-free survival (PFS)
 392 information, representing the time to first recurrence after chemotherapy. These
 393 analyses were performed using datasets from three independent cohorts:
 394 PRJNA866991 (n=41), GSE32062 (n=260), and GSE102073 (n=70). It is

395 important to note that these cohorts utilized bulk transcriptome data, where gene
 396 expression represents the expression level of the entire sample rather than a
 397 specific cell group. Additionally, these data were only retrieved from pre-
 398 chemotherapy conditions. We thus first identified DE genes that were
 399 significantly overexpressed in the whole sample of PD_before when compared to
 400 PR1_before and PR2_before. Subsequent survival analyses of these genes
 401 revealed that only two genes, BMP1 and TPM2, were significantly associated
 402 with low PFS across all three cohorts (Figure 4A). Both genes were also
 403 significantly overexpressed in Epithelial cells_0 cells in the PD patient when
 404 compared to samples of PR patients (Figure 4B).



405 **Figure 4** (A) Kaplan-Meier survival curves on progression-free survival (PFS) for genes BMP1 and TPM2 from
 406 three independent cohorts. (B) Violin plots showing gene expression level patterns among samples at the sample level
 407 before chemotherapy and at the Epithelial cells_0 level after chemotherapy. (C) Sample clustering revealing that
 408 the expression profiles of Ciliated-secretory intermediate cells were clustered based on individual patients rather
 409 than treatment condition.

411

412 We also investigated chemoresistant genes in ciliated-secretory
413 intermediate cells since they were also remained in the PD_after, and are assumed
414 to be the main origin of the high-grade serous ovarian carcinoma (HGSOC)
415 (24,25). Similar to Epithelial cells_0 cells, sample clustering also revealed that
416 the expression profiles of ciliated-secretory intermediate cells were clustered
417 based on individual patients rather than treatment condition (Figure 4C). There
418 were only 17 genes overexpressed in Epithelial cells_0 cells when compared to
419 ciliated-secretory intermediate cells in the PD_after with no pathways enriched,
420 indicating their similar transcriptional profiles. This indicated that ciliated-
421 secretory intermediate cells in the PD_after could also be chemoresistant, and the
422 corresponding transcriptional profiles were also pre-existing in individual
423 patients before treatment.

424

425 **The induced fibroblasts after chemotherapy are key cells for** 426 **chemoresistance**

427


428 We initially identified four fibroblasts subclusters (Figure 5A).
429 Fibroblasts_0 occupied a large proportion in the tumor microenvironment after
430 chemotherapy, indicating its association with chemotherapy. Notably,
431 Fibroblasts_0 was difficult to be clearly separated from Fibroblasts_1 in the
432 UMAP plot with different resolutions, indicating that Fibroblasts_0 cells were
433 induced from Fibroblasts_1 during the treatment. Transcriptional dynamics
434 analysis also revealed that the transcriptional dynamics direction of Fibroblasts_1
435 before chemotherapy changed to the same direction of Fibroblasts_0 after
436 chemotherapy, except for a small portion of cells whose direction was more
437 inclined towards the pre-treatment direction. However, no DE gene was
438 specifically found to be overexpressed in this part. Additionally, when we
439 conducted sampling clustering using cellular average transcriptional profiles, we
440 found that unlike other subclusters, Fibroblasts_0 was always clustered together

441 with Fibroblasts_1 in each sample (Figure 5B and 5C). We thus treated
442 Fibroblasts_0 and Fibroblasts_1 as one cluster named Fibroblasts_01, and
443 differentiated pre-chemotherapy and post-chemotherapy clusters into
444 Fibroblasts_01_before and Fibroblasts_01_after (Figure 5D, Figure 5E and 5F).

445
446 All identified fibroblasts were epithelial-mesenchymal transition (EMT)
447 fibroblasts, as evidenced by their high expression of corresponding markers VIM,
448 ZEB1, and ZEB2 (Figure 5G). Although no genes were specifically
449 overexpressed in Fibroblasts_01_before, several genes were specifically
450 overexpressed in Fibroblasts_01_after after chemotherapy. The top five
451 overexpressed DE genes for Fibroblasts_01_after in the PD_after were SGCZ,
452 ACSM3, STAR, ESYT2, and INSR. Three pathways were enriched for this
453 subcluster, including ovarian steroidogenesis, longevity regulating pathway-
454 multiple species, and FoxO signaling pathway. The corresponding genes were
455 IGF1R, INSR, STAR, FOXO1, and SGK1. Additionally, Fibroblasts_2 (FAP⁺
456 COL8A1⁺ RUNX2⁺) specifically overexpressed FAP, COL8A1, and RUNX2,
457 and enrichment in pathways related to ovarian steroidogenesis, regulation of actin
458 cytoskeleton, AGE-RAGE signaling pathway in diabetic complications, and
459 amoebiasis. Fibroblasts_3 (MCAM⁺) specifically overexpressed MCAM and
460 enriched pathways such as pathways in cancer, cortisol synthesis and secretion,
461 vascular smooth muscle contraction, and cGMP-PKG signaling pathway (Figure
462 5H and 5I).

463
464 The sample clustering tree using average transcriptional profiles showed
465 that all subclusters were clustered by treatment condition rather than patient IDs
466 (Figure 5D), signifying that treatment condition played a critical role in
467 fibroblasts among patients. When examining the enrichment of overexpressed
468 genes in the PD_after compared to PR1_after and PR2_after for each subcluster,
469 only overexpressed genes in the Fibroblasts_01_after enriched many cancer-

470 related signaling pathways, indicating that Fibroblasts_01_after in the PD_after
 471 exhibited a high degree of malignancy (Figure 5J). Combined with the abundance
 472 after treatment for Fibroblasts_01_after (Figure 5A), we thus proposed that
 473 Fibroblasts_01_after cells were the key cells for chemotherapy responses.



474


475

476 **Figure 5** (A) The UMAP plot of cell atlas for fibroblasts subclusters with different resolutions. Left: the UMAP
 477 plot of cell atlas for fibroblasts subclusters in integrated samples. Middle: the UMAP plot of cell atlas for
 478 fibroblasts subclusters in each sample among patients before and after chemotherapy. Right: transcriptional
 479 dynamic depicted by RNA velocity for each subcluster. (B) Sampling clustering using cellular average
 480 transcriptional profiles for fibroblasts subclusters under resolution 0.12. (C) Sampling clustering using cellular
 481 average transcriptional profiles for fibroblasts subclusters under resolution 0.05. (D) Sampling clustering using
 482 cellular average transcriptional profiles for fibroblasts subclusters after treating Fibroblasts_0 and Fibroblasts_1

483 as one subcluster, and differentiated pre-chemotherapy and post-chemotherapy clusters into
484 Fibroblasts_01_before and Fibroblasts_01_after. (E) UMAP plot of fibroblast subclusters in integrated samples.
485 (F) UMAP plot of fibroblast subclusters in each sample from patients before and after chemotherapy. (G) Violin
486 plots depicting the expression of epithelial-mesenchymal transition (EMT) markers in each subcluster. (H) Dot
487 plot showing marker gene expression in fibroblast subclusters. (I) KEGG pathway enrichment analysis for
488 fibroblast subclusters. (J) KEGG pathway enrichment for overexpressed genes in the PD_after for each subcluster.
489 PD_after: Post-chemotherapy sample of the chemoresistant patient. PD_before: Pre-chemotherapy sample of the
490 chemoresistant patient. PR1_after: Post-chemotherapy sample of patient 1 with partial response to chemotherapy.
491 PR1_before: Pre-chemotherapy sample of patient 1 with partial response to chemotherapy. PR2_after: Post-
492 chemotherapy sample of patient 2 with partial response to chemotherapy. PR2_before: Pre-chemotherapy sample
493 of patient 2 with partial response to chemotherapy.

494

495 Gene co-expression networks construction revealed five network modules
496 for Fibroblasts_01_after cells in total (Figure 6A and 6B). The M2 module was
497 significantly overexpressed in the PD_after when compared to either PR1_after
498 or PR2_after, indicating its chemoresistance characters (Figure 6C). Protein-
499 protein network using hub genes of this module that overexpressed in the
500 PD_after revealed two subnetworks. One was formed by many cholesterol
501 biosynthesis-related genes, such as HMGCR, SREBF2, MSMO1, MVD, ACAT2
502 and INSIG1. The other subnetwork was formed by well-known cancer promoting
503 genes such as MYC and STAT3 (Figure 6D), and enriched in many cancer-related
504 pathways such as HIF-1 signaling pathway, insulin resistance, JAK-STAT
505 signalling pathway, and type II diabetes mellitus.



506
507 **Figure 6** Gene co-expression networks construction and comparisons for Fibroblasts_01_after. (A) The UMAP
508 plots of the hub gene signature score of five modules constructed for Epithelial cells_0. (B) Violin plots of the
509 harmonized module eigengenes (hMEs) in each post-treatment sample for each module. (D) Differential module
510 eigengene comparisons between PD_after and PR1_after or PR2_after, respectively. (E) Co-expression network
511 visualization using hub genes of Module 2. PD_after: post-chemotherapy sample of the chemoresistant patient.
512 PR1_after: post-chemotherapy sample of the patient 1 with partial response to chemotherapy. PR2_after: post-
513 chemotherapy sample of the patient 2 with partial response to chemotherapy.

514
515 **Other stromal cells and immune cells in the microenvironment were**
516 **generally tumour-promoting among patients after chemotherapy**

517
518 We identified four macrophage subclusters (Figure 7), including CD163⁺
519 M2 macrophages (Macrophages_0), hypoxic macrophages (Macrophages_1)
520 which overexpressed hypoxia-related genes (HK2⁺) (26), RRM2⁺ M2
521 macrophages (Macrophages_2), and fibrosis-like macrophages (Macrophages_3)
522 that overexpressed fibroblast-related genes (PDGFRA⁺ and CALD1⁺), consistent
523 with previous reports of macrophages being capable of transdifferentiating into


524 myofibroblasts (27). Following chemotherapy, a large proportion of
525 Macrophages_0 cells and a few Macrophages_1 cells remained in the PD_after.
526 Only 31 genes were found to be overexpressed in the PD_after compared to
527 PR1_after and PR2_after for Macrophages_0, and no genes were overexpressed
528 in the PD_after for Macrophages_1.

529

530 Furthermore, we identified five T cell subclusters (Figure 7), including
531 CD8⁺THEMIS⁺ T cells [21,22] (T cells_0), natural killer (NK) cells
532 (NCAM1⁺CD3⁻) (28) (T cells_1), CD4⁺ regulatory T cells (Tregs)
533 (CD4⁺CTLA4⁺FOXP3⁺IL2RA⁺) (29) (T cells_2), TOP2A⁺ T cells (30) (T
534 cells_3), and MEG3⁺ T cells (31–33) (T cells_4). The CD8⁺ THEMIS⁺ T cells
535 represented a large proportion after treatment. Only 14 genes were found to be
536 overexpressed in the PD_after compared to PR1_after and PR2_after, and no
537 specific pathway enrichment was observed. A small proportion of NKT-like cells
538 remained in the PR1_after and the PD_after, with no DE genes identified between
539 them. These results indicated a generally similar immunosuppressive
540 microenvironment after chemotherapy among patients.

541

542 Regarding Lymphatic endothelial cells (Figure 1), only four genes were
543 overexpressed in the PD_after, including RMST, STAT3, NAMPT, and YBX3.
544 For Schwann cells (Figure 1), no DE genes were identified among patients after
545 treatment. Similarly, for Endothelial cells (Figure 1), only 47 DE genes were
546 found to be overexpressed in the PD_after compared to PR1_after and PR2_after,
547 such as NAMPT, SEMA3A, RMST, and ATP1B3, and no significantly enriched
548 pathways were observed. These results indicated that these stromal cells
549 exhibited generally similar characteristics after chemotherapy among patients.



550

551 **Figure 7** (A) Left: UMAP plot of macrophage subclusters for integrated samples. Middle: UMAP plot of
 552 macrophage subclusters for each sample among patients before and after chemotherapy. Right: Dot plot of marker
 553 gene expression in each macrophage subcluster. (B) Left: UMAP plot of T cell subclusters for integrated samples.
 554 Middle: UMAP plot of T cell subclusters for each sample among patients before and after chemotherapy. Right:
 555 Dot plot of marker gene expression in each T cell subcluster. PD_after: Post-chemotherapy sample of the
 556 chemoresistant patient. PD_before: Pre-chemotherapy sample of the chemoresistant patient. PR1_after: Post-
 557 chemotherapy sample of patient 1 with partial response to chemotherapy. PR1_before: Pre-chemotherapy sample
 558 of patient 1 with partial response to chemotherapy. PR2_after: Post-chemotherapy sample of patient 2 with partial
 559 response to chemotherapy. PR2_before: Pre-chemotherapy sample of patient 2 with partial response to
 560 chemotherapy.

561

562 **The NAMPT-INSR was the most prioritized ligand-receptor pair enriched**
 563 **in the chemoresistance patient**

564

565 Cell-cell interactions play crucial roles in executing cellular functions.
 566 Since Epithelia cells_0 cells and Fibroblasts_01_after cells were key cells for
 567 chemoresistance, we thus would like to see which cells interacted with them and


568 affected their core genes expression. The genes that were significantly
569 overexpressed in Epithelial cells_0 cells in the PD_after in M3 and M4 modules
570 we identified above were used as the target geneset when Epithelial cells_0 cells
571 were as the receivers. Similarly, the genes that were significantly overexpressed
572 in Fibroblasts_01_after cells in the PD_after in M2 module we identified above
573 were used as the target genesets when Fibroblasts_01_after cells were as the
574 receivers.

575


576 Interestingly, results consistently showed that the NAMPT-INSR was the
577 most prioritized ligand-receptor pair for cells interacting with Epithelial cells_0
578 cells (receiver cells) in the PD_after when compared to PR1_after and PR2_after.
579 For example, INSR was the most potentially interacted receptor for NAMPT for
580 Fibroblasts_01_after cells (sender) interacting with Epithelial cells_0 cells
581 (receiver) in the PD_after compared to PR1_after (Figure 8A left) and PR2_after
582 (Figure 8B left). NAMPT was the only ligand with high ranking for ligand
583 activity, and also with high expression level in Fibroblasts_01_after in the
584 PD_after compared to PR1_after (Figure 8A right) and PR2_after (Figure 8B
585 right). The corresponding downstream target genes were IL1R and INSR in the
586 PD_after compared to PR1 (Figure 8A right) and PR2 (Figure 8B right). These
587 results were also applied to other cells interacting with Epithelial cells_0 cells in
588 the PD_after to drive the overexpression of IL1R and INSR as the downstream
589 genes, such as Endothelial cells, Fibroblasts_2, Fibroblasts_3, Lymphatic
590 endothelial cells, and T cells_0, which were given in the Supplementary File 3.

591

592 The NAMPT-INSR was also the most prioritized ligand-receptor pair for
593 cells interacting with Fibroblasts_01_after cells (receiver) in the PD_after when
594 compared to PR1_after and PR2_after, with MYC and INSR itself as the
595 downstream target genes, such as Fibroblasts_3 and Lymphatic endothelial cells
596 (Figure 8C and 8D, Supplementary File 3).



597



598

599

600

601

602

603

Figure 8 Cell-cell interactions analyses. (A) Ligand-receptor inference (left) and target genes inference (right) when Fibroblasts_01_after cells acted as senders and interacted with Epithelial_cells_0 cells as receivers in the PD_after compared to PR1_after. The NAMPT-INSR was the most prioritized ligand receptor pair, with IL1R and INSR itself as the downstream target genes. (B) Ligand-receptor inference (left) and target genes inference (right) when Fibroblasts_01_after cells acted as senders and interacted with Epithelial_cells_0 cells as receivers

604 in the PD_after compared to PR2_after. The NAMPT-INSR was the most prioritized ligand receptor pair, with
605 IL1R and INSR itself as the downstream target genes. (C) Ligand-receptor inference (left) and target genes
606 inference (right) when Fibroblasts_3 cells acted as senders and interacted with Fibroblasts_01_after cells as
607 receivers in the PD_after compared to PR1_after. The NAMPT-INSR was the most prioritized ligand receptor
608 pair, with MYC and INSR itself as the downstream target genes. (D) Ligand-receptor inference (left) and target
609 genes inference (right) when Fibroblasts_3 cells acted as senders and interacted with Fibroblasts_01_after cells
610 as receivers in the PD_after compared to PR2_after. The NAMPT-INSR was the most prioritized ligand receptor
611 pair, with MYC and INSR itself as the downstream target genes. PD_after: Post-chemotherapy sample of the
612 chemoresistant patient. PR1_after: Post-chemotherapy sample of patient 1 with partial response to chemotherapy.
613 PR2_after: Post-chemotherapy sample of patient 2 with partial response to chemotherapy.

614

615 **Discussion**

616 In this study, we revealed that chemoresistant cancer cells were pre-
617 existing in individual patients prior to treatment. This observation aligns with
618 existing research that cancer cells are often clustered by patient IDs, highlighting
619 the strong individual differences among cancer cells (34,35), which can
620 contribute to the heterogeneity of tumors in individual patients. These results
621 provide a foundation for developing biomarkers to diagnose chemoresistance
622 before initiating treatment. We identified BMP1 and TPM2 as promising
623 universal candidate biomarkers for identifying chemoresistant patients before
624 treatment when using bulk transcriptome data. Both genes can facilitate
625 chemoresistance (36,37), supporting the rationality of our analyses.

626

627 We found two co-expression network modules were significantly
628 overexpressed in Epithelial cells_0 cells in the chemoresistant sample. One
629 network was formed with hub genes such as ESR1 and CTNNB1. The other
630 module network was formed by tight connections among genes of IGF1R and
631 INSR, AR, NCOR2 and SMAD2. CTNNB1 has been suggested as a potential
632 biomarker for chemoresistance in breast cancer (38), which can be a good
633 candidate therapeutic target for chemoresistance in HGSOC. Notably, two
634 hormone-related genes, ESR1 and AR, were involved in these core networks.
635 Hormone imbalance can contribute to the development of ovarian cancer, and

636 both androgen and estrogen have been reported to regulate proliferation and
637 progression in ovarian cancer (39,40). Our findings here thus highlight the critical
638 roles of these hormones in chemoresistance in HGSOC which deserve
639 consideration. Additionally, two hub genes are insulin receptors (IGF1R and
640 INSR). The enrichment of insulin resistance pathway in Epithelial cells_0 cells
641 in the chemoresistant sample further supports the potential link between insulin
642 and early chemoresistance. Insulin is well-known for cellular metabolism and
643 growth (41). It is known that chemotherapy-induced insulin resistance can impair
644 anti-cancer efficacy (42). Elevated circulating insulin due to insulin resistance,
645 coupled with overexpressed insulin receptors in cancer cells can confer a
646 selective advantage to promote proliferation and migration (43,44), and thus
647 contributing to chemoresistance in HGSOC. Our findings thus underscore the
648 importance of insulin-related genes in early chemoresistance in HGSOC.

649

650 In addition to cancer cells, other cells in the tumor microenvironment can
651 also play crucial roles in chemotherapy responses. Unlike the pre-existing cancer
652 cells, our findings indicated that the induced fibroblasts (Fibroblasts_01_after)
653 following chemotherapy were key cells associated with chemoresistance. A
654 subnetwork formed by cholesterol biosynthesis-related genes was found in the
655 module that was significantly overexpressed in Fibroblasts_01_after cells in the
656 chemoresistant sample. Cholesterol biosynthesis can support cancer progression
657 and also induce drug resistance (45). For example, gene SREBF2 has been
658 reported to facilitate chemoresistance in ovarian cancer (46). Our results thus
659 implies the importance of cholesterol metabolism in chemoresistance in HGSOC.
660 Another subnetwork was formed by cancer-related genes such as STAT3 and
661 MYC. The overexpression of both genes have well been linked to
662 chemoresistance in ovarian cancer (47,48). Genes within these subnetworks
663 could have critical roles in chemoresistance and are good candidate targets.

664

665 Cellular interactions in the tumor microenvironment are vital for
666 chemoresistance. Our analysis revealed that the NAMPT-INSR was the most
667 prioritized ligand-receptor pair enriched in the chemoresistant sample when cells
668 interacting with the two key cell types, i.e. Epithelial cells_0 and
669 Fibroblasts_01_after. NAMPT as a rate-limiting enzyme for NAD synthesis, is
670 required for cellular metabolism and DNA repair, for example, as the substrate
671 of PARPs (a DNA repair enzyme whose inhibitors are widely used in second-line
672 therapy for HGSOC) (49). Recent studies have highlighted the potential function
673 of NAMPT as an alternative ligand for INSR (50), which can enhance insulin
674 resistance (51), which can impair anti-cancer efficacy as we mentioned above.
675 Besides, similar to insulin, NAMPT can stimulate glucose uptake and
676 proliferation through INSR to confer a selective advantage to promote
677 proliferation and migration of cancer cells as we mentioned above. Moreover,
678 NAMPT treatment can induce fibrosis by overproducing profibrotic molecules
679 through the INSR transduction pathway (51). This can contribute to
680 chemoresistance by creating a physical barrier to protect from chemotherapeutic
681 drugs (52). All these findings gave strong supports for the involvement of
682 NAMPT-INSR in chemoresistance in HGSOC patients. We further identified that
683 IL1R1, MYC and INSR were the downstream target genes of NAMPT-INSR.
684 MYC and INSR can induced chemoresistance as we mentioned above. The
685 chemoresistant functions of these target genes gave further support that NAMPT-
686 INSR can have critical roles in chemoresistance in HGSOC patients, although the
687 specific mechnism involved in HGSOC needs further investigation.

688
689 Notably, NAMPT was overexpressed in Fibroblasts_01_after cells only
690 after chemotherapy. This aligns with previous findings about the overexpression
691 of NAMPT at the onset of drug resistance (53). NAMPT can be induced by
692 hypoxia via a STAT3-dependent mechanism (54). Additionally, MYC can
693 interact with the NAMPT promoter and stimulate its expression to promote

694 cancer (55,56). The overexpression of both STAT3 and MYC in the PD_after in
695 Fibroblasts_01_after cells in our study can help explain the overexpression of
696 NAMPT in these cells after chemotherapy. Our cellular interactions analyses
697 showed that MYC was also the downstream target gene of NAMPT in
698 Fibroblasts_01_after in the PD_after. Indeed, MYC and NAMPT are involved in
699 a positive feedback loop to drive tumorigenesis (56). The consistent results
700 supported the reliability of our analyses.

701
702 The immune microenvironment in patients with varying chemotherapy
703 responses exhibited a general trend of being inhibited and proinflammatory after
704 chemotherapy. The proportions of T cells, both before and after chemotherapy,
705 were observed to be small, which aligns with the characteristic of ovarian cancer
706 being a “cold” tumor (57). Notably, Ciliated-secretory intermediate cells
707 displayed a close transcriptional profile with Epithelial cells_0 cells in the
708 PD_after, consistent with the hypothesis that they are the primary origin of
709 HGSOC, originating from the fallopian tube and fall off to the ovary (24,25).
710 Although other stromal cells showed minimal differences in gene expression
711 among samples after chemotherapy, the majority of them exhibited
712 overexpression of NAMPT in the chemoresistant patient. This is in line with the
713 findings that the NAMPT-INSR pair was highly enriched when these stromal
714 cells interacted with Fibroblasts_01_after cells and Epithelial cells_0 cells in the
715 chemoresistant patient (Supplementary File 3).

716

717 **Conclusions**

718 In conclusion, we found that pre-existing cancer cells and induced
719 fibroblasts as key contributors for early chemoresistance in HGSOC patients.
720 Metabolism reprogramming, involving hormone-related genes (ESR1 and AR),
721 insulin-related genes (IGF1R and INSR) and cholesterol biosynthesis-related
722 genes, could play critical roles in early chemoresistant HGSOC. CTNNB1,

723 STAT3 and MYC as core hub genes are also good candidate chemoresistant
724 targets. The NAMPT-INSR ligand-receptor pair enriched for cells interacted with
725 Fibroblasts_01_after cells and Epithelial cells_0 cells, can be important for early
726 chemoresistance in HGSOC.

727

728 We thus propose that the combination of chemotherapy with INSR
729 inhibitors and NAMPT inhibitors could represent a promising treatment strategy
730 for early chemoresistant HGSOC patients. The inhibitors of NAMPT and INSR
731 have undergone extensive development and clinical testing (58,59). Previous
732 research has demonstrated that the combination of a NAMPT inhibitor and
733 chemotherapy resulted in a better prognosis than chemotherapy alone in mice
734 with HGSOC (60), holds promise for further improving the therapeutic window.
735 Despite the limitations in sample size, our study has yielded valuable clinic
736 findings, enrich the heterogeneous library of HGSOC and could offer important
737 insights into potential clinical biomarkers and therapeutic targets for HGSOC
738 chemoresistance. The findings from our study may also contribute to
739 advancements in understanding and addressing chemoresistance in various
740 cancer types in a broad sense.

741

742 **Acknowledgments**

743 We thank the valuable suggestions from Yunfei Zhao and Prof. Canwei
744 Xia. We also would like to acknowledge the computer support provided by Prof.
745 Yang Liu, Yuqing Han, and Ximin He.

746

747 **Funding**

748 This study was supported by the National Key R&D Program of China
749 (2022YFC2704200), the National Natural Science Foundation of China
750 (81903037), the Natural Science Foundation of Guangdong Province, China
751 (2020A1515011281), and the Nature Science Foundation of China

752 (No.81772769). Part of the data computation was supported by National
753 Supercomputer Center in Guangzhou, China.

754

755 **Authors contributions**

756 Langyu Gu and Guofen Yang proposed the study. Langyu Gu conducted
757 the single nuclei transcriptome data analyses. Shasha He and Yu Zeng conducted
758 chemotherapy responses evaluation. Linxiang Wu proposed the sampling plan
759 and provided the clinical information. Guofen Yang, Hongwei Shen, and
760 Linxiang Wu conducted the sampling. Langyu Gu, Yang Zhang, Chuling Wu,
761 and Huishan Xu conducted survival analyses. Langyu Gu, Chenqing Zheng, and
762 Xiaoyan Zhang conducted pathways enrichment analyses. Guofen Yang, Yufeng
763 Ren, Shasha He, and Shuzhong Yao provided funding supports. Langyu Gu wrote
764 the manuscript, with all authors providing comments and approval.

765

766 **References**

- 767 1. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck
768 A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. *J Natl Compr*
769 *Canc Netw*. 2019;17:896–909.
- 770 2. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. *Lancet* (London,
771 England). 2014;384:1376–88.
- 772 3. Gonzalez Bosquet J, Newton AM, Chung RK, Thiel KW, Ginader T, Goodheart MJ, et
773 al. Prediction of chemo-response in serous ovarian cancer. *Mol Cancer*. 2016;15:66.
- 774 4. Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance
775 Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. *Cell*.
776 2018;173:879–93.e13.
- 777 5. Qin P, Chen H, Wang Y, Huang L, Huang K, Xiao G, et al. Cancer-associated fibroblasts
778 undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell
779 and spatial transcriptomics. *Cell Rep Med*. 2023;4:101231.
- 780 6. Sharma A, Cao EY, Kumar V, Zhang X, Leong HS, Wong AML, et al. Longitudinal
781 single-cell RNA sequencing of patient-derived primary cells reveals drug-induced
782 infidelity in stem cell hierarchy. *Nat Commun*. 2018;9:4931.
- 783 7. Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, et al. Longitudinal
784 single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic
785 ovarian cancer. *Sci Adv*. 2022;8:eabm1831.
- 786 8. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response
787 rates to second-line platinum-based therapy in ovarian cancer patients challenge the
788 clinical definition of platinum resistance. *Gynecol Oncol*. 2018;150.
- 789 9. Joo Hyun O, Lodge MA, Wahl RL. Practical perclist: A simplified guide to PET response
790 criteria in solid tumors 1.0. *Radiology*. 2016;280.

- 791 10. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated
792 analysis of multimodal single-cell data. *Cell*. 2021;184:3573–87.
- 793 11. McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-
794 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Sys*. 2019;8:329–
795 37.
- 796 12. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The
797 STRING database in 2023: protein-protein association networks and functional
798 enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res*.
799 2023;51:D638–46.
- 800 13. Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, et al. Delineating copy number
801 and clonal substructure in human tumors from single-cell transcriptomes. *Nat*
802 *Biotechnol*. 2021;39:599–608.
- 803 14. Morabito S, Reese F, Rahimzadeh N, Miyoshi E, Swarup V. hdWGCNA identifies co-
804 expression networks in high-dimensional transcriptomics data. *Cell Reports Methods*.
805 2023; 3:100498.
- 806 15. Therneau T, Grambsch P. *Modeling Survival Data: Extending the Cox Model*. Springer,
807 New York; 2000.
- 808 16. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and
809 genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol*. 2019;37:907–15.
- 810 17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
811 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25:2078–9.
- 812 18. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
813 Alignment / Map (SAM) Format and SAMtools 1000 Genome Project Data Processing
814 Subgroup. *Bioinformatics*. 2009; 25:2078-9.
- 815 19. Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for
816 assigning sequence reads to genomic features. *Bioinformatics*. 2014;30:923-930.
- 817 20. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
818 RNA-seq data with DESeq2. *Genome Biol*. 2014;15:550.
- 819 21. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - Analysis of Affymetrix GeneChip
820 data at the probe level. *Bioinformatics*. 2004;20:307-315.
- 821 22. Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by
822 linking ligands to target genes. *Nat Methods*. 2020;17:159–62.
- 823 23. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to
824 transient cell states through dynamical modeling. *Nat Biotechnol*. 2020;38:1408–14.
- 825 24. Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al. The Repertoire of
826 Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing
827 of Normal Fallopian Tube Epithelial Cells. *Cancer Cell*. 2020;37:226–42.
- 828 25. Dinh HQ, Lin X, Abbasi F, Nameki R, Haro M, Olingy CE, et al. Single-cell
829 transcriptomics identifies gene expression networks driving differentiation and
830 tumorigenesis in the human fallopian tube. *Cell Rep*. 2021;35:108978.
- 831 26. Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A, Sica A. Hypoxia-mediated
832 regulation of macrophage functions in pathophysiology. *Int Immunol*. 2013;25:67–75.
- 833 27. Tang PC-T, Chung JY-F, Xue VW-W, Xiao J, Meng X-M, Huang X-R, et al. Smad3
834 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast
835 Transition. *Adv Sci*. 2022;9:e2101235.
- 836 28. Väyrynen JP, Haruki K, Lau MC, Väyrynen SA, Ugai T, Akimoto N, et al. Spatial
837 Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker
838 Analysis of the Colorectal Cancer Microenvironment. *Cancer Immunol Res* .
839 2022;10:215–27.
- 840 29. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T

- 841 Cells and Human Disease. *Annu Rev Immunol.* 2020;38:541–66.
- 842 30. Li Y, Wang Z, Han F, Zhang M, Yang T, Chen M, et al. Single-cell transcriptome
843 analysis profiles cellular and molecular alterations in submandibular gland and blood in
844 IgG4-related disease. *Ann Rheum Dis.* 2023;82:1348–58.
- 845 31. Li J-Q, Hu S-Y, Wang Z-Y, Lin J, Jian S, Dong Y-C, et al. Long non-coding RNA
846 MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of
847 Treg/Th17 in immune thrombocytopenic purpura. *Biomed Pharmacother.* 2016;83:905–
848 11.
- 849 32. Qiu Y-Y, Wu Y, Lin M-J, Bian T, Xiao Y-L, Qin C. LncRNA-MEG3 functions as a
850 competing endogenous RNA to regulate Treg/Th17 balance in patients with asthma by
851 targeting microRNA-17/ ROR γ t. *Biomed Pharmacother.* 2019;111:386–94.
- 852 33. Wang J, Liu X, Hao C, Lu Y, Duan X, Liang R, et al. MEG3 modulates TIGIT
853 expression and CD4 + T cell activation through absorbing miR-23a. *Mol Cell Biochem.*
854 2019;454:67–76.
- 855 34. Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor
856 heterogeneity and the microenvironment in advanced non-small cell lung cancer. *Nat*
857 *Commun.* 2021;12:2540.
- 858 35. Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, et al. A single-cell landscape
859 of high-grade serous ovarian cancer. *Nat Med.* 2020;26:1271–9.
- 860 36. Zhang J, Zhang J, Xu S, Zhang X, Wang P, Wu H, et al. Hypoxia-Induced TPM2
861 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.
862 *Cell Physiol Biochem.* 2018;45:692–705.
- 863 37. Xie F, Zhang D, Qian X, Wei H, Zhou L, Ding C, et al. Analysis of cancer-promoting
864 genes related to chemotherapy resistance in esophageal squamous cell carcinoma. *Ann*
865 *Transl Med.* 2022;10:92.
- 866 38. Ozcan G. PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to
867 neoadjuvant chemotherapy in ER+/HER2- breast cancer. *Front Oncol.*
868 2023;13:1216438.
- 869 39. Chung WM, Chen L, Chang WC, Su SY, Hung YC, Ma WL. Androgen/androgen
870 receptor signaling in ovarian cancer: Molecular regulation and therapeutic potentials.
871 *Int. J. Mol. Sci.* 2021; 22:7748.
- 872 40. Rothenberger NJ, Somasundaram A, Stabile LP. The role of the estrogen pathway in the
873 tumor microenvironment. *Int. J. Mol. Sci.* 2018; 19:611.
- 874 41. Le TKC, Dao XD, Nguyen DV, Luu DH, Bui TMH, Le TH, et al. Insulin signaling and
875 its application. *Front. Endocrinol. (Lausanne).* 2023; 14:1226655.
- 876 42. Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EGE, Jalving M. Cancer-drug
877 induced insulin resistance: innocent bystander or unusual suspect. *Cancer Treat Rev.*
878 2015;41:376–84.
- 879 43. Vigneri R, Sciacca L, Vigneri P. Rethinking the Relationship between Insulin and
880 Cancer. *Trends Endocrinol Metab.* 2020;31:551–60.
- 881 44. Belfiore A, Malaguarnera R. Insulin receptor and cancer. *Endocr Relat Cancer.*
882 2011;18:R125–47.
- 883 45. Huang B, Song B liang, Xu C. Cholesterol metabolism in cancer: mechanisms and
884 therapeutic opportunities. *Nat. Metab.* 2020; 2:132-141.
- 885 46. Zheng L, Li L, Lu Y, Jiang F, Yang X-A. SREBP2 contributes to cisplatin resistance in
886 ovarian cancer cells. *Exp Biol Med (Maywood).* 2018;243:655–62.
- 887 47. Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, et al. miR-137 mediates the functional
888 link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
889 *Oncogene.* 2019;38:564–80.
- 890 48. Gong K, Dong Y, Wang L, Duan Y, Yu J, Sun Y, et al. Nanoparticle overcomes

- 891 sphingosine-1-phosphate receptor-1-mediated chemoresistance through inhibiting
892 s1pr1/ p-stat3 axis in ovarian carcinoma. *Int J Nanomedicine*. 2020; 15:5561-5571.
- 893 49. Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, et al.
894 Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
895 *Oncotarget*. 2016;7:2968–84.
- 896 50. Peng Q, Jia SH, Parodo J, Ai Y, Marshall JC. Pre-B cell colony enhancing factor induces
897 Nampt-dependent translocation of the insulin receptor out of lipid microdomains in
898 A549 lung epithelial cells. *Am J Physiol Endocrinol Metab*. 2015;308:E324–33.
- 899 51. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: a new player
900 in mesangial cell physiology and diabetic nephropathy. *Am J Physiol Renal Physiol*.
901 2008;295:F1485–94.
- 902 52. Tajaldini M, Poorkhani A, Amiriani T, Amiriani A, Javid H, Aref P, et al. Strategy of
903 targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling
904 new era to cancer chemo-immunotherapy resistance. *Eur J Pharmacol*.
905 2023;957:175991.
- 906 53. Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide
907 Phosphoribosyltransferase in Malignancy: A Review. *Genes and Cancer*. 2013; 4:447-
908 56.
- 909 54. Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide
910 phosphoribosyltransferase in ovarian cancers. *Int J Clin Exp Pathol*. 2010;3:522–7.
- 911 55. Wei Y, Xiang H, Zhang W. Review of various NAMPT inhibitors for the treatment of
912 cancer. *Front Pharmacol*. 2022;13:970553.
- 913 56. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The c-
914 MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1
915 deacetylase form a positive feedback loop. *Proc Natl Acad Sci U S A*. 2012;109:E187–
916 96.
- 917 57. Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and
918 future perspectives. *Clin Immunol*. 2021;226:108707.
- 919 58. Tang H, Wang L, Wang T, Yang J, Zheng S, Tong J, et al. Recent advances of targeting
920 nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery. *Eur J*
921 *Med Chem*. 2023;258:115607.
- 922 59. Zhang X, Zhu X, Bi X, Huang J, Zhou L. The Insulin Receptor: An Important Target
923 for the Development of Novel Medicines and Pesticides. *Int J Mol Sci*. 2022; 23:7793.
- 924 60. Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, et al.
925 NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-
926 Induced Senescence in Ovarian Cancer. *Cancer Res*. 2020;80:890–900.
- 927